Veradermics reports first positive efficacy data for oral minoxidil in women with pattern hair loss

Veradermics announced that its oral formulation of minoxidil demonstrated positive efficacy in a mid‑stage trial involving women with pattern hair loss.

The results mark the company's first efficacy win in female patients, expanding the market potential for its flagship hair‑loss asset.

If the data are confirmed in later studies, the company could pursue broader commercial opportunities, though additional development and regulatory steps remain ahead.